Respiratory syncytial virus vaccine development

References

• Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet375, 1545–1555 (2010).
   PubMed Web of Science ®Google Scholar
• Karron RA, Singleton RJ, Bulkow L et al. Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska Study Group. J. Infect. Dis.180, 41–49 (1999).
   PubMed Web of Science ®Google Scholar
• Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J. Virol.82, 2040–2055 (2008).
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Iwane MK et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med.360, 588–598 (2009).
   PubMed Web of Science ®Google Scholar
• Schickli JH, Dubovsky F, Tang RS. Challenges in developing a pediatric RSV vaccine. Hum. Vaccin.5, 582–591 (2009).
   PubMed Web of Science ®Google Scholar
• Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol. Rev.239, 149–166 (2011).
   PubMed Web of Science ®Google Scholar
• Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J. Infect. Dis.183, 16–22 (2001).
   PubMed Web of Science ®Google Scholar
• Shay DK, Holman RC, Newman RD et al. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA282, 1440–1446 (1999).
   PubMed Web of Science ®Google Scholar
• Paramore LC, Mahadevia PJ, Piedra PA. Outpatient RSV lower respiratory infections among high-risk infants and other pediatric populations. Pediatr. Pulmonol.45, 578–584 (2010).
   PubMed Web of Science ®Google Scholar
• Hall CB. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med.344, 1917–1928 (2001).
   PubMed Web of Science ®Google Scholar
• Bourgeois FT, Valim C, McAdam AJ, Mandl KD. Relative impact of influenza and respiratory syncytial virus in young children. Pediatrics124, e1072–e1080 (2009).
   PubMed Web of Science ®Google Scholar
• Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J. Pediatr.137, 865–870 (2000).
   PubMed Web of Science ®Google Scholar
• Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine21, 3479–3482 (2003).
   PubMed Web of Science ®Google Scholar
• Lewis DB, Wilson CB. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In: Infectious Diseases of the Fetus and the Newborn Infant (6th Edition). Remington JS, Klein J, Baker C, Wilson C (Eds). Saunders, Philadelphia, PA, USA, 87–210 (2005).
   Google Scholar
• Stensballe LG, Ravn H, Kristensen K et al. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J. Pediatr.154, 296–298 (2009).
   PubMed Web of Science ®Google Scholar
• Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J. Pediatr.98, 708–715 (1981).
   PubMed Web of Science ®Google Scholar
• Collins PL, Crowe JE. Respiratory syncytial virus and metapneumovirus. In: Fields Virology. Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (Eds). Lippincott Williams & Wilkins, PA, USA, 1601–1646 (2007).
   Google Scholar
• El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age. Pediatrics121, 235–243 (2008).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med.352, 1749–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Treanor JJ, Betts RF, Walsh EE. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J. Am. Geriatr. Soc.40, 115–119 (1992).
   PubMed Web of Science ®Google Scholar
• Duncan CB, Walsh EE, Peterson DR, Lee FE, Falsey AR. Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults. J. Infect. Dis.200, 1242–1246 (2009).
   PubMed Web of Science ®Google Scholar
• King JC Jr, Burke AR, Clemens JD et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. Pediatr. Infect. Dis. J.12, 733–739 (1993).
   Google Scholar
• Kim YJ, Boeckh M,Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin. Respir. Crit. Care Med.28, 222–242 (2007).
   PubMed Web of Science ®Google Scholar
• King JC Jr. Community respiratory viruses in individuals with human immunodeficiency virus infection. Am. J. Med.102, 19–24 (1997).
   PubMedGoogle Scholar
• Simoes EA, Carbonell-Estrany X, Rieger CH et al. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J. Allergy Clin. Immunol.126, 256–262 (2010).
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Lemanske RF Jr. The role of respiratory virus infections in childhood asthma inception. Immunol. Allergy Clin. North Am.30, 513–522, vi (2010).
   Google Scholar
• Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis.163, 693–698 (1991).
   PubMed Web of Science ®Google Scholar
• DeVincenzo J, Lambkin-Williams R, Wilkinson T et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl Acad. Sci. USA107, 8800–8805 (2010).
   PubMed Web of Science ®Google Scholar
• Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst. Rev.1, CD000181 (2007).
   Google Scholar
• Malley R, DeVincenzo J, Ramilo O et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis.178, 1555–1561 (1998).
   PubMed Web of Science ®Google Scholar
• Simoes EA, Groothuis JR, Carbonell-Estrany X et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J. Pediatr.151, 34–42 (2007).
   PubMed Web of Science ®Google Scholar
• Butt ML, Symington A, Janes M et al. The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study. Eur. J. Pediatr.170(7), 907–913 (2010).
   Google Scholar
• Gan SW, Ng L, Lin X, Gong X, Torres J. Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain. Protein Sci.17, 813–820 (2008).
   PubMed Web of Science ®Google Scholar
• Roberts SR, Lichtenstein D, Ball LA, Wertz GW. The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons. J. Virol.68, 4538–4546 (1994).
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Yang L, Fricke J et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J. Virol.82, 12191–12204 (2008).
   PubMed Web of Science ®Google Scholar
• Hendricks DA, McIntosh K, Patterson JL. Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J. Virol.62, 2228–2233 (1988).
   PubMed Web of Science ®Google Scholar
• Sugrue RJ, Brown C, Brown G, Aitken J, McL RH. Furin cleavage of the respiratory syncytial virus fusion protein is not a requirement for its transport to the surface of virus-infected cells. J. Gen. Virol.82, 1375–1386 (2001).
   Google Scholar
• Dutch RE, Hagglund RN, Nagel MA, Paterson RG, Lamb RA. Paramyxovirus fusion (F) protein: a conformational change on cleavage activation. Virology281, 138–150 (2001).
   Google Scholar
• Russell CJ, Luque LE. The structural basis of paramyxovirus invasion. Trends Microbiol.14, 243–246 (2006).
   PubMed Web of Science ®Google Scholar
• Kurt-Jones EA, Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol.1, 398–401 (2000).
   PubMed Web of Science ®Google Scholar
• Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. New insights for development of a safe and protective RSV vaccine. Hum. Vaccin.6, 482–492 (2010).
   PubMed Web of Science ®Google Scholar
• Lo MS, Brazas RM, Holtzman MJ. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and α/β interferon responsiveness. J. Virol.79, 9315–9319 (2005).
   PubMed Web of Science ®Google Scholar
• Kolokoltsov AA, Deniger D, Fleming EH et al. Small interfering RNA profiling reveals key role of clathrin-mediated endocytosis and early endosome formation for infection by respiratory syncytial virus. J. Virol.81, 7786–7800 (2007).
   PubMed Web of Science ®Google Scholar
• Levine AM, Whitsett JA. Pulmonary collectins and innate host defense of the lung. Microbes Infect.3, 161–166 (2001).
   PubMed Web of Science ®Google Scholar
• Feldman SA, Audet S, Beeler JA. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J. Virol.74, 6442–6447 (2000).
   PubMed Web of Science ®Google Scholar
• Techaarpornkul S, Collins PL, Peeples ME. Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology294, 296–304 (2002).
   PubMed Web of Science ®Google Scholar
• Hallak LK, Spillmann D, Collins PL, Peeples ME. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J. Virol.74, 10508–10513 (2000).
   PubMed Web of Science ®Google Scholar
• Behera AK, Matsuse H, Kumar M et al. Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection. Biochem. Biophys. Res. Commun.280, 188–195 (2001).
   PubMed Web of Science ®Google Scholar
• Tripp RA, Jones LP, Haynes LM et al. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol.2, 732–738 (2001).
   PubMed Web of Science ®Google Scholar
• Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J. Med. Virol.78, 169–177 (2006).
   PubMed Web of Science ®Google Scholar
• Thomson SA, Jaramillo AB, Shoobridge M et al. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine23, 4647–4657 (2005).
   PubMedGoogle Scholar
• Cohen J. AIDS vaccines. HIV dodges one-two punch. Science305, 1545–1547 (2004).
   PubMed Web of Science ®Google Scholar
• Crotty S, Felgner P, Davies H et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol.171, 4969–4973 (2003).
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Slifka MK, Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol. Rev.211, 320–337 (2006).
   PubMed Web of Science ®Google Scholar
• Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity8, 363–372 (1998).
   PubMed Web of Science ®Google Scholar
• Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its Eradication. WHO, Geneva, Switzerland (1988).
   Google Scholar
• Kapp JA, Pierce CW, Benacerraf B. Genetic control of immune responses in vitro. I. Development of primary and secondary plaque-forming cell responses to the random terpolymer 1-glutamic acid 60–61-alanine30–1-tyrosine10 (GAT) by mouse spleen cells in vitro. J. Exp. Med.138, 1107–1120 (1973).
   Google Scholar
• Murphy K, Travers P, Walport M. Janeway’s Immunobiology. Garland Science, NY, USA (2008).
   Google Scholar
• Rudraraju R, Surman S, Jones B et al. Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut. Virology410, 429–436 (2011).
   PubMed Web of Science ®Google Scholar
• Sealy R, Jones BG, Surman SL, Hurwitz JL. Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1. Vaccine28, 6749–6756 (2010).
   PubMed Web of Science ®Google Scholar
• Hyland L, Sangster M, Sealy R, Coleclough C. Respiratory virus infection of mice provokes a permanent humoral immune response. J. Virol.68, 6083–6086 (1994).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr. Infect. Dis. J.28, S66–S76 (2009).
   PubMed Web of Science ®Google Scholar
• Clark HF, Offit PA, Plotkin SA, Heaton PM. The new pentavalent rotavirus vaccine composed of bovine (strain WC3)-human rotavirus reassortants. Pediatr. Infect. Dis. J.25, 577–583 (2006).
   PubMed Web of Science ®Google Scholar
• Mallery DL, McEwan WA, Bidgood SR et al. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc. Natl Acad. Sci. USA107, 19985–19990 (2010).
   PubMed Web of Science ®Google Scholar
• Baumgarth N, Choi YS, Rothaeusler K, Yang Y, Herzenberg LA. B cell lineage contributions to antiviral host responses. Curr. Top. Microbiol. Immunol.319, 41–61 (2008).
   Google Scholar
• Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS4, 388–393 (2009).
   PubMed Web of Science ®Google Scholar
• Neumann AU, Phillips S, Levine I et al. Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. Hepatology52, 875–885 (2010).
   PubMed Web of Science ®Google Scholar
• He W, Ladinsky MS, Huey-Tubman KE et al. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature455, 542–546 (2008).
   PubMedGoogle Scholar
• Null D Jr, Pollara B, Dennehy PH et al. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr. Infect. Dis. J.24, 1021–1023 (2005).
   PubMed Web of Science ®Google Scholar
• Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J. Infect. Dis.190, 373–378 (2004).
   PubMed Web of Science ®Google Scholar
• Prince GA, Horswood RL, Chanock RM. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J. Virol.55, 517–520 (1985).
   PubMed Web of Science ®Google Scholar
• Prince GA, Hemming VG, Horswood RL, Baron PA, Chanock RM. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J. Virol.61, 1851–1854 (1987).
   PubMed Web of Science ®Google Scholar
• Siber GR, Leombruno D, Leszczynski J et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J. Infect. Dis.169, 1368–1373 (1994).
   PubMed Web of Science ®Google Scholar
• Sun JC, Williams MA, Bevan MJ. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat. Immunol.5, 927–933 (2004).
   PubMed Web of Science ®Google Scholar
• Williams MA, Holmes BJ, Sun JC, Bevan MJ. Developing and maintaining protective CD8+ memory T cells. Immunol. Rev.211, 146–153 (2006).
   PubMed Web of Science ®Google Scholar
• Brown SA, Hurwitz JL, Zirkel A et al. A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein. J. Virol.81, 12535–12542 (2007).
   Google Scholar
• Surman SL, Brown SA, Jones BG, Woodland DL, Hurwitz JL. Clearance of HIV type 1 envelope recombinant Sendai virus depends on CD4(+) T cells and interferon-γ but not B cells, CD8(+) T cells, or perforin. AIDS Res. Hum. Retroviruses26(7), 783–793 (2010).
   PubMedGoogle Scholar
• Maric M, Arunachalam B, Phan UT et al. Defective antigen processing in GILT-free mice. Science294, 1361–1365 (2001).
   PubMed Web of Science ®Google Scholar
• Nussbaum AK, Kuttler C, Hadeler KP, Rammensee HG, Schild H. PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics53, 87–94 (2001).
   PubMed Web of Science ®Google Scholar
• van der Most RG, Concepcion RJ, Oseroff C et al. Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice. J. Virol.71, 5110–5114 (1997).
   PubMedGoogle Scholar
• Hale JS, Wubeshet M, Fink PJ. TCR revision generates functional CD4+ T cells. J. Immunol.185, 6528–6534 (2010).
   Google Scholar
• Vela JL, it-Azzouzene D, Duong BH, Ota T, Nemazee D. Rearrangement of mouse immunoglobulin κ deleting element recombining sequence promotes immune tolerance and λ B cell production. Immunity28, 161–170 (2008).
   PubMedGoogle Scholar
• Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell49, 273–280 (1987).
   PubMed Web of Science ®Google Scholar
• Pullen AM, Marrack P, Kappler JW. The T-cell repertoire is heavily influenced by tolerance to polymorphic self-antigens. Nature335, 796–801 (1988).
   PubMed Web of Science ®Google Scholar
• Kappler JW, Staerz U, White J, Marrack PC. Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex. Nature332, 35–40 (1988).
   PubMed Web of Science ®Google Scholar
• Kelso A. Th1 and Th2 subsets: paradigms lost? Immunol. Today16, 374–379 (1995).
   PubMedGoogle Scholar
• Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol.7, 145–173 (1989).
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol.136, 2348–2357 (1986).
   PubMed Web of Science ®Google Scholar
• Coffman R, Shrader B, Carty J, Mosmann T, Bond M. A mouse T cell product that preferentially enhances IgA production. J. Immunol.139, 3685–3690 (1987).
   PubMed Web of Science ®Google Scholar
• Lutzker S, Rothman P, Pollock R, Coffman R, Alt FW. Mitogen- and IL-4-regulated expression of germ-line Ig γ 2b transcripts: evidence for directed heavy chain class switching. Cell53, 177–184 (1988).
   PubMed Web of Science ®Google Scholar
• Crother TR, Schroder NW, Karlin J et al.Chlamydia pneumoniae infection induced allergic airway sensitization is controlled by regulatory T-cells and plasmacytoid dendritic cells. PLoS ONE6, e20784 (2011).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell133, 775–787 (2008).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol.155, 1151–1164 (1995).
   PubMed Web of Science ®Google Scholar
• Murphy TJ, Ni CN, Zang Y, Mannick JA, Lederer JA. CD4+CD25+ regulatory T cells control innate immune reactivity after injury. J. Immunol.174, 2957–2963 (2005).
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat. Immunol.6, 353–360 (2005).
   PubMed Web of Science ®Google Scholar
• Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity28, 454–467 (2008).
   PubMed Web of Science ®Google Scholar
• Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J. Immunol.165, 6107–6115 (2000).
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Zou L et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol.178, 6730–6733 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu J, Paul WE. Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol. Rev.238, 247–262 (2010).
   PubMed Web of Science ®Google Scholar
• Heath WR, Belz GT, Behrens GM et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev.199, 9–26 (2004).
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM. On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol.32, 2385–2392 (2002).
   Google Scholar
• Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat. Immunol.5, 678–684 (2004).
   PubMed Web of Science ®Google Scholar
• Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J. Virol.75, 4594–4603 (2001).
   PubMed Web of Science ®Google Scholar
• Ottolini MG, Blanco JC, Eichelberger MC et al. The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J. Gen. Virol.86, 2823–2830 (2005).
   PubMed Web of Science ®Google Scholar
• Boukhvalova MS, Prince GA, Blanco JC. The cotton rat model of respiratory viral infections. Biologicals37, 152–159 (2009).
   PubMed Web of Science ®Google Scholar
• de WL, Power UF, Yuksel S et al. Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine22, 915–922 (2004).
   Google Scholar
• Tang RS, MacPhail M, Schickli JH et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J. Virol.78, 11198–11207 (2004).
   PubMed Web of Science ®Google Scholar
• Karron RA, Wright PF, Crowe JE Jr et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J. Infect. Dis.176, 1428–1436 (1997).
   PubMed Web of Science ®Google Scholar
• Wright PF, Ikizler MR, Gonzales RA et al. Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract. J. Virol.79, 8651–8654 (2005).
   Google Scholar
• Guo-Parke H, Canning P, Douglas I et al. Comparative RSV cytopathogenesis in well-differentiated paediatric airway epithelial cell models derived from the upper and lower respiratory tracts. Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p45).
   Google Scholar
• Parker J, Sarlang S, Thavagnanam S et al. A 3-D well-differentiated model of pediatric bronchial epithelium demonstrates unstimulated morphological differences between asthmatic and nonasthmatic cells. Pediatr. Res.67, 17–22 (2010).
   PubMedGoogle Scholar
• Herold S, Steinmueller M, von Wulffen W et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J. Exp. Med.205, 3065–3077 (2008).
   PubMed Web of Science ®Google Scholar
• Herold S, von WW, Steinmueller M et al. Alveolar epithelial cells direct monocyte transepithelial migration upon influenza virus infection: impact of chemokines and adhesion molecules. J. Immunol.177, 1817–1824 (2006).
   PubMed Web of Science ®Google Scholar
• Fulginiti VA, Eller JJ, Sieber OF et al. Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol.89, 435–448 (1969).
   PubMed Web of Science ®Google Scholar
• Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol.89, 449–463 (1969).
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol.89, 405–421 (1969).
   PubMed Web of Science ®Google Scholar
• Polack FP, Teng MN, Collins PL et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med.196, 859–865 (2002).
   PubMed Web of Science ®Google Scholar
• Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J. Clin. Microbiol.26, 1595–1597 (1988).
   PubMed Web of Science ®Google Scholar
• Murphy BR, Prince GA, Walsh EE et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Clin. Microbiol.24, 197–202 (1986).
   PubMed Web of Science ®Google Scholar
• Prince GA, Curtis SJ, Yim KC, Porter DD. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J. Gen. Virol.82, 2881–2888 (2001).
   PubMed Web of Science ®Google Scholar
• Connors M, Giese NA, Kulkarni AB et al. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol.68, 5321–5325 (1994).
   PubMed Web of Science ®Google Scholar
• Kim EY, Battaile JT, Patel AC et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat. Med.14, 633–640 (2008).
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol.89, 422–434 (1969).
   PubMed Web of Science ®Google Scholar
• Shaw CA, Otten G, Wack A et al. Antibody affinity maturation and respiratory syncytial virus disease. Nat. Med.15, 725–726 (2009).
   Google Scholar
• Haynes LM, Moore DD, Kurt-Jones EA et al. Involvement of Toll-like receptor 4 in innate immunity to respiratory syncytial virus. J. Virol.75, 10730–10737 (2001).
   PubMed Web of Science ®Google Scholar
• Awomoyi AA, Rallabhandi P, Pollin TI et al. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J. Immunol.179, 3171–3177 (2007).
   PubMed Web of Science ®Google Scholar
• Paulus SC, Hirschfeld AF, Victor RE et al. Common human Toll-like receptor 4 polymorphisms – role in susceptibility to respiratory syncytial virus infection and functional immunological relevance. Clin. Immunol.123, 252–257 (2007).
   PubMedGoogle Scholar
• Puthothu B, Forster J, Heinzmann A, Krueger M. TLR-4 and CD14 polymorphisms in respiratory syncytial virus associated disease. Dis. Markers22, 303–308 (2006).
   PubMed Web of Science ®Google Scholar
• Tal G, Mandelberg A, Dalal I et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J. Infect. Dis.189, 2057–2063 (2004).
   PubMed Web of Science ®Google Scholar
• Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest.88, 1026–1033 (1991).
   PubMed Web of Science ®Google Scholar
• Srikiatkhachorn A, Braciale TJ. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med.186, 421–432 (1997).
   PubMed Web of Science ®Google Scholar
• Varga SM, Wang X, Welsh RM, Braciale TJ. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity15, 637–646 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson TR, Varga SM, Braciale TJ, Graham BS. Vβ14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J. Virol.78, 8753–8760 (2004).
   PubMed Web of Science ®Google Scholar
• Welliver RC Sr. The immune response to respiratory syncytial virus infection: friend or foe? Clin. Rev. Allergy Immunol.34, 163–173 (2008).
   Google Scholar
• Mobbs KJ, Smyth RL, O’Hea U et al. Cytokines in severe respiratory syncytial virus bronchiolitis. Pediatr. Pulmonol.33, 449–452 (2002).
   PubMedGoogle Scholar
• Garofalo RP, Patti J, Hintz KA et al. Macrophage inflammatory protein-1α (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J. Infect. Dis.184, 393–399 (2001).
   PubMed Web of Science ®Google Scholar
• Chen ZM, Mao JH, Du LZ, Tang YM. Association of cytokine responses with disease severity in infants with respiratory syncytial virus infection. Acta Paediatr.91, 914–922 (2002).
   PubMedGoogle Scholar
• Brandenburg AH, Kleinjan A, van Het LB et al. Type 1-like immune response is found in children with respiratory syncytial virus infection regardless of clinical severity. J. Med. Virol.62, 267–277 (2000).
   PubMed Web of Science ®Google Scholar
• Boukhvalova MS, Prince GA, Soroush L et al. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine24, 5027–5035 (2006).
   PubMed Web of Science ®Google Scholar
• Plotnicky H, Siegrist CA, Aubry JP et al. Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate. Vaccine21, 2651–2660 (2003).
   PubMed Web of Science ®Google Scholar
• Fishaut M, Tubergen D, McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J. Pediatr.96, 179–186 (1980).
   PubMed Web of Science ®Google Scholar
• Rosenberg HF, Dyer KD, Domachowske JB. Respiratory viruses and eosinophils: exploring the connections. Antiviral Res.83, 1–9 (2009).
   PubMed Web of Science ®Google Scholar
• Phipps S, Lam CE, Mahalingam S et al. Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood110, 1578–1586 (2007).
   PubMed Web of Science ®Google Scholar
• Olson MR, Varga SM. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J. Immunol.179, 5415–5424 (2007).
   PubMed Web of Science ®Google Scholar
• Stevens WW, Sun J, Castillo JP, Braciale TJ. Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease. Viral Immunol.22, 243–251 (2009).
   PubMed Web of Science ®Google Scholar
• Lee DC, Harker JA, Tregoning JS et al. CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J. Virol.84, 8790–8798 (2010).
   Google Scholar
• Radu GU, Caidi H, Miao C et al. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice. J. Virol.84, 9632–9636 (2010).
   PubMed Web of Science ®Google Scholar
• van Drunen Littel-van den Hurk S, Latimer L, Brownlie R et al. Formulation of respiratory syncytial virus vaccine with a novel adjuvant platform induces a protective immune response in cotton rats. Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p151).
   Google Scholar
• Ripple MJ, You D, Honnegowda S et al. Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease. J. Immunol.185, 4804–4811 (2010).
   PubMed Web of Science ®Google Scholar
• Power UF, Plotnicky H, Blaecke A, Nguyen TN. The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B. Vaccine22, 168–176 (2003).
   PubMed Web of Science ®Google Scholar
• Goetsch L, Plotnicky-Gilquin H, Champion T et al. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate. Vaccine18, 2735–2742 (2000).
   Google Scholar
• Dagouassat N, Robillard V, Haeuw JF et al. A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine. Vaccine19, 4143–4152 (2001).
   PubMed Web of Science ®Google Scholar
• Power UF, Plotnicky-Gilquin H, Huss T et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology230, 155–166 (1997).
   PubMed Web of Science ®Google Scholar
• Power UF, Nguyen TN, Rietveld E et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect. Dis.184, 1456–1460 (2001).
   PubMed Web of Science ®Google Scholar
• Kneyber MC, Kimpen JL. Advances in respiratory syncytial virus vaccine development. Curr. Opin. Investig. Drugs.5, 163–170 (2004).
   PubMedGoogle Scholar
• Durbin AP, Karron RA. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin. Infect. Dis.37, 1668–1677 (2003).
   PubMed Web of Science ®Google Scholar
• Libon C, Nguyen T, Helffer K et al. Cross protective anti-RSV A and B immune responses induced after injection with G2Na alone versus combined G2Na/G2Nb in BALB/c mice and in cotton rats. Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p153).
   Google Scholar
• Prince GA, Capiau C, Deschamps M et al. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. J. Virol.74, 10287–10292 (2000).
   PubMed Web of Science ®Google Scholar
• Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect. Dis.177, 467–469 (1998).
   PubMed Web of Science ®Google Scholar
• Simoes EA, Tan DH, Ohlsson A, Sales V, Wang EE. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine20, 954–960 (2001).
   PubMed Web of Science ®Google Scholar
• Wathen MW, Kakuk TJ, Brideau RJ et al. Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge. J. Infect. Dis.163, 477–482 (1991).
   PubMed Web of Science ®Google Scholar
• Oien NL, Brideau RJ, Walsh EE, Wathen MW. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine12, 731–735 (1994).
   PubMed Web of Science ®Google Scholar
• Brideau RJ, Walters RR, Stier MA, Wathen MW. Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein. J. Gen. Virol.70, 2637–2644 (1989).
   PubMed Web of Science ®Google Scholar
• Gonzalez IM, Karron RA, Eichelberger M et al. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine18, 1763–1772 (2000).
   PubMed Web of Science ®Google Scholar
• Piedra PA, Cron SG, Jewell A et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine21, 2448–2460 (2003).
   PubMed Web of Science ®Google Scholar
• Piedra PA, Grace S, Jewell A et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr. Infect. Dis. J.15, 23–31 (1996).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE, Capellan J et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines – nonadjuvanted vaccine or vaccine adjuvanted with alum – given concomitantly with influenza vaccine to high-risk elderly individuals. J. Infect. Dis.198, 1317–1326 (2008).
   PubMed Web of Science ®Google Scholar
• Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine21, 3465–3467 (2003).
   PubMed Web of Science ®Google Scholar
• Swanson KA, Settembre EC, Shaw CA et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc. Natl Acad. Sci. USA108, 9619–9624 (2011).
   PubMed Web of Science ®Google Scholar
• Langley JM, Sales V, McGeer A et al. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. Vaccine27, 5913–5919 (2009).
   PubMed Web of Science ®Google Scholar
• McLellan JS, Chen M, Kim A et al. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat. Struct. Mol. Biol.17, 248–250 (2010).
   PubMed Web of Science ®Google Scholar
• McLellan JS, Chen M, Chang JS et al. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J. Virol.84, 12236–12244 (2010).
   PubMed Web of Science ®Google Scholar
• Anderson R, Huang Y, Langley JM. Prospects for defined epitope vaccines for respiratory syncytial virus. Future Microbiol.5(4), 585–602 (2010).
   PubMedGoogle Scholar
• Ofek G, Guenaga FJ, Schief WR et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl Acad. Sci. USA107, 17880–17887 (2010).
   PubMed Web of Science ®Google Scholar
• Liang X, Munshi S, Shendure J et al. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine17, 2862–2872 (1999).
   PubMed Web of Science ®Google Scholar
• D’Costa S, Slobod KS, Webster RG, White SW, Hurwitz JL. Structural features of HIV envelope defined by antibody escape mutant analysis. AIDS Res. Hum. Retroviruses17, 1205–1209 (2001).
   Google Scholar
• Gerhard W, Yewdell J, Frankel ME, Webster R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature290, 713–717 (1981).
   PubMed Web of Science ®Google Scholar
• Webster RG, Brown LE, Laver WG. Antigenic and biological characterization of influenza virus neuraminidase (N2) with monoclonal antibodies. Virology135, 30–42 (1984).
   Google Scholar
• Sealy R, Chaka W, Surman S et al. Target peptide sequence within infectious human immunodeficiency virus type 1 does not ensure envelope-specific T-helper cell reactivation: influences of cysteine protease and gamma interferon-induced thiol reductase activities. Clin. Vaccine Immunol.15, 713–719 (2008).
   Google Scholar
• Arnold PY, La Gruta NL, Miller T et al. The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues. J. Immunol.169, 739–749 (2002).
   PubMedGoogle Scholar
• Moudgil KD, Sercarz EE, Grewal IS. Modulation of the immunogenicity of antigenic determinants by their flanking residues. Immunol. Today19, 217–220 (1998).
   PubMedGoogle Scholar
• Surman S, Lockey TD, Slobod KS et al. Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc. Natl Acad. Sci. USA98, 4587–4592 (2001).
   PubMed Web of Science ®Google Scholar
• McDevitt HO, Chinitz A. Genetic control of the antibody response: relationship between immune response and histocompatibility (H-2) type. Science163, 1207–1208 (1969).
   PubMed Web of Science ®Google Scholar
• Hamdy S, Haddadi A, Shayeganpour A, Samuel J,Lavasanifar A. Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles. Pharm. Res.28(9), 2288–2301 (2011).
   PubMed Web of Science ®Google Scholar
• Kasturi SP, Skountzou I, Albrecht RA et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature470, 543–547 (2011).
   PubMed Web of Science ®Google Scholar
• Adair BM. Nanoparticle vaccines against respiratory viruses. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.1, 405–414 (2009).
   PubMed Web of Science ®Google Scholar
• De Haan A, Muhammad S, Wilschut J. Mucosal immunization strategies for induction of respiratory syncytial virus-specific immunity. Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p154).
   Google Scholar
• Nagai Y, Kato A. Paramyxovirus reverse genetics is coming of age. Microbiol. Immunol.43, 613–624 (1999).
   PubMed Web of Science ®Google Scholar
• Wright PF, Karron RA, Belshe RB et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis.182, 1331–1342 (2000).
   PubMed Web of Science ®Google Scholar
• Karron RA, Wright PF, Belshe RB et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis.191, 1093–1104 (2005).
   PubMed Web of Science ®Google Scholar
• Buchholz U, Luongo C, Winter C et al. Live attenuated RSV and HMPV vaccines. Presented at: 7th Internationial Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstact p135).
   Google Scholar
• Luongo C, Yang L, Winter CC et al. Codon stabilization analysis of the ‘248’ temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates. Vaccine27, 5667–5676 (2009).
   PubMed Web of Science ®Google Scholar
• Jin H, Cheng X, Traina-Dorge VL et al. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine21, 3647–3652 (2003).
   PubMed Web of Science ®Google Scholar
• Liang X. A live attenuated respiratory syncytial virus vaccine candidate produced by serial VERO cell passage. Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p145).
   Google Scholar
• Widjojoatmodjo MN, Boes J, van Remmerden Y et al. A highly attenuated recombinant human RSV lacking the G protein confers long time protection against RSV infection in cotton rats. Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p149).
   Google Scholar
• Widjojoatmodjo MN, Boes J, van BM et al. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virol. J.7, 114 (2010).
   PubMed Web of Science ®Google Scholar
• Kamphuis T, Stegmann T, Merijerhof T, De Haan A, Wilschut J. A virosomal respiratory syncytial virus vaccine with intrinsic adjuvant properties. Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p137).
   Google Scholar
• Stegmann T, Kamphuis T, Meijerhof T et al. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: a safe and immunogenic non-replicating vaccine formulation. Vaccine28, 5543–5550 (2010).
   PubMed Web of Science ®Google Scholar
• Openshaw P, Sawant D, Olszewska W et al. PEV4: a novel virosomal vaccine that induces strong neutralizing antibody and protects mice against RSV infection. Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p148).
   Google Scholar
• Buchholz UJ, Granzow H, Schuldt K et al. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. J. Virol.74, 1187–1199 (2000).
   PubMed Web of Science ®Google Scholar
• Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J. Virol.80, 1130–1139 (2006).
   PubMed Web of Science ®Google Scholar
• McGinnes LW, Gravel KA, Finberg RW et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J. Virol.85, 366–377 (2011).
   PubMed Web of Science ®Google Scholar
• Murawski MR, McGinnes LW, Finberg RW et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J. Virol.84, 1110–1123 (2010).
   PubMed Web of Science ®Google Scholar
• Tang RS, Spaete RR, Thompson MW et al. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine26, 6373–6382 (2008).
   PubMed Web of Science ®Google Scholar
• Bernstein D, Malkin E, Charenkavanich S, Dubovsky F. Safety profile, immunogenicity, and viral shedding of MEDI-534, a live, attenuated respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine in RSV/PIV3 seronegative children. Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p139).
   Google Scholar
• Bousse T, Chambers RL, Scroggs RA, Portner A, Takimoto T. Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment. Virus Res.121, 23–32 (2006).
   PubMed Web of Science ®Google Scholar
• Jones B, Zhan X, Mishin V et al. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine27, 1848–1857 (2009).
   PubMed Web of Science ®Google Scholar
• Takimoto T, Hurwitz JL, Zhan X et al. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral Immunol.18, 255–266 (2005).
   PubMed Web of Science ®Google Scholar
• Zhan X, Hurwitz JL, Krishnamurthy S et al. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Vaccine25, 8782–8793 (2007).
   PubMed Web of Science ®Google Scholar
• Zhan X, Slobod KS, Krishnamurthy S et al. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections. Vaccine26, 3480–3488 (2008).
   PubMed Web of Science ®Google Scholar
• Takimoto T, Hurwitz JL, Coleclough C et al. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J. Virol.78, 6043–6047 (2004).
   PubMed Web of Science ®Google Scholar
• Slobod KS, Shenep JL, Lujan-Zilbermann J et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine22, 3182–3186 (2004).
   PubMed Web of Science ®Google Scholar
• Hurwitz JL, Soike KF, Sangster MY et al. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one. Vaccine15, 533–540 (1997).
   PubMed Web of Science ®Google Scholar
• Hurwitz JL, Shenep JL, Portner A. Advancement of a Sendai virus-based RSV vaccine. Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p136).
   Google Scholar
• Collins PL, Purcell RH, London WT et al. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine8, 164–168 (1990).
   PubMed Web of Science ®Google Scholar
• Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm.Rep.52, 1–28 (2003).
   PubMedGoogle Scholar
• Grabenstein JD, Winkenwerder W Jr. US military smallpox vaccination program experience. JAMA289, 3278–3282 (2003).
   PubMed Web of Science ®Google Scholar
• Sano J, Chaitman BR, Swindle J, Frey SE. Electrocardiography screening for cardiotoxicity after modified Vaccinia Ankara vaccination. Am. J. Med.122, 79–84 (2009).
   Google Scholar
• Gudmundsdotter L, Nilsson C, Brave A et al. Recombinant modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine27, 4468–4474 (2009).
   PubMed Web of Science ®Google Scholar
• Hawkridge T, Scriba TJ, Gelderbloem S et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J. Infect. Dis.198, 544–552 (2008).
   PubMed Web of Science ®Google Scholar
• Jordan I, Northoff S, Thiele M et al. A chemically defined production process for highly attenuated poxviruses. Biologicals39, 50–58 (2011).
   PubMed Web of Science ®Google Scholar
• Li X, Sambhara S, Li CX et al. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology269, 54–65 (2000).
   PubMed Web of Science ®Google Scholar
• Bembridge GP, Rodriguez N, Garcia-Beato R et al. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J. Gen. Virol.81, 2519–2523 (2000).
   PubMed Web of Science ®Google Scholar
• Park EK, Soh BY, Jang YS, Park JH, Chung GH. Immune induction and modulation in mice following immunization with DNA encoding F protein of respiratory syncytial virus. Mol. Cells12, 50–56 (2001).
   Google Scholar
• Vaughan K, Rhodes GH, Gershwin LJ. DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys. Vaccine23, 2928–2942 (2005).
   PubMedGoogle Scholar
• Wu H, Dennis VA, Pillai SR, Singh SR. RSV fusion (F) protein DNA vaccine provides partial protection against viral infection. Virus Res.145, 39–47 (2009).
   Google Scholar
• Graham BS, Kines RC, Corbett KS et al. Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination. Mucosal Immunol.3, 475–486 (2010).
   PubMed Web of Science ®Google Scholar
• Lodmell DL, Ray NB, Ewalt LC. Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection. Vaccine16, 115–118 (1998).
   PubMed Web of Science ®Google Scholar
• Torres CA, Iwasaki A, Barber BH, Robinson HL. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J. Immunol.158, 4529–4532 (1997).
   PubMed Web of Science ®Google Scholar
• Richmond JFL, Mustafa F, Lu S et al. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology230, 265–274 (1997).
   PubMedGoogle Scholar
• Brown SA, Surman SL, Sealy R et al. Heterologous prime–boost HIV-1 vaccination regimens in pre-clinical and clinical trials. Viruses2, 435–467 (2010).
   PubMed Web of Science ®Google Scholar
• Abbink P, Lemckert AA, Ewald BA et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol.81, 4654–4663 (2007).
   PubMed Web of Science ®Google Scholar
• Thorner AR, Vogels R, Kaspers J et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J. Clin. Microbiol.44, 3781–3783 (2006).
   PubMed Web of Science ®Google Scholar
• Roberts DM, Nanda A, Havenga MJ et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature441, 239–243 (2006).
   PubMed Web of Science ®Google Scholar
• Xiang Z, Gao G, Reyes-Sandoval A et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol.76, 2667–2675 (2002).
   PubMed Web of Science ®Google Scholar
• Kim S, Jang JE, Yu JR, Chang J. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection. Vaccine28, 3801–3808 (2010).
   PubMed Web of Science ®Google Scholar
• Liljestrom P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (NY)9, 1356–1361 (1991).
   PubMedGoogle Scholar
• Riezebos-Brilman A, de MA, Bungener L et al. Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. J. Clin. Virol.35, 233–243 (2006).
   Google Scholar
• Chen M, Hu KF, Rozell B et al. Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J. Immunol.169, 3208–3216 (2002).
   PubMed Web of Science ®Google Scholar
• Crowe J, Mok H, Hedgecock J, Shepherd B, Johnston R. Alphavirus-based respiratory syncytial virus vaccine induces protection mediated by both humoral and cellular responses, even in the presence of passively-acquired antibodies. Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p142).
   Google Scholar
• Mok H, Lee S, Utley TJ et al. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J. Virol.81, 13710–13722 (2007).
   PubMed Web of Science ®Google Scholar
• Cautivo KM, Bueno SM, Cortes CM et al. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette–Guerin promotes virus clearance and protects from infection. J. Immunol.185, 7633–7645 (2010).
   PubMed Web of Science ®Google Scholar
• Xie C, He JS, Zhang M et al. Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium. Hum. Gene Ther.18, 746–752 (2007).
   PubMedGoogle Scholar
• Falcone V, Mihm D, Neumann-Haefelin D et al. Systemic and mucosal immunity to respiratory syncytial virus induced by recombinant Streptococcus gordonii surface-displaying a domain of viral glycoprotein G. FEMS Immunol. Med. Microbiol.48, 116–122 (2006).
   Google Scholar
• Lau JM, Korban SS. Transgenic apple expressing an antigenic protein of the human respiratory syncytial virus. J. Plant Physiol.167, 920–927 (2010).
   PubMed Web of Science ®Google Scholar
• Grunwald T, Tenbusch M, Hannaman D et al. Immunogenicity of different delivery strategies of RSV DNA vaccines in rhesus monkeys. Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p143).
   Google Scholar
• Lee S, Currier M, Stokes K, Celis E, Moore M. B cell and peptide based immunotherapy vaccine for respiratory cyncytial virus infection. Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p150).
   Google Scholar
• Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science233, 1318–1321 (1986).
   PubMed Web of Science ®Google Scholar
• Goff SL, Smith FO, Klapper JA et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J. Immunother.33, 840–847 (2010).
   Google Scholar
• Picard O, Giral P, Defer MC et al. AIDS vaccine therapy: Phase I trial. Lancet336, 179 (1990).
   Google Scholar
• Picard O, Lebas J, Imbert JC, Bigel P, Zagury D. Complication of intramuscular/subcutaneous immune therapy in severely immune-compromised individuals. J. Acquir. Immune Defic. Syndr.4, 641–643 (1991).
   Google Scholar
• Boyman O, Krieg C, Letourneau S, Pantaleo G. Insight into mechanism of IL-2-induced toxicity provides rationale for improved treatment strategy using IL-2/mAb complexes. J. Immunol.182(April 2009 Meeting Abstract Suppl.), 38.8 (2009).
   Google Scholar
• Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med.355, 1018–1028 (2006).
   PubMed Web of Science ®Google Scholar
• Gardner K. Cytokine storm and an anti-CD28 monoclonal antibody. N. Engl. J. Med.355, 2591–2592 (2006).
   Google Scholar
• Fu YH, He JS, Wang XB et al. A prime–boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus. Biochem. Biophys. Res. Commun.395, 87–92 (2010).
   PubMed Web of Science ®Google Scholar
• Murphy BR, Olmsted RA, Collins PL, Chanock RM, Prince GA. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J. Virol.62, 3907–3910 (1988).
   PubMed Web of Science ®Google Scholar
• Kurugol Z, Erensoy S, Aksit S, Egemen A, Bilgic A. Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5-year follow-up study. Vaccine19, 3936–3939 (2001).
   PubMedGoogle Scholar
• Zhao Z, Smith PJ, Luman ET. Trends in early childhood vaccination coverage: progress towards US Healthy People 2010 goals. Vaccine27, 5008–5012 (2009).
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect. Dis.7, 658–666 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh EE, Peterson DR,Falsey AR. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible? J. Infect. Dis.195, 1046–1051 (2007).
   PubMed Web of Science ®Google Scholar
• Falsey AR. RSV in adults: What do we know? What do we need to know? Where are we going? Presented at: 7th International Respiratory Syncytial Virus Symposium. Rotterdam, The Netherlands, 12 December 2010 (Abstract p81).
   Google Scholar